Brian Abrahams

Joseph Schwartz

Eliana Merle

Eric Joseph

Gena Wang

Joel Beatty

John Peyton Bohnsack

Kelly Shi

Kristen Kluska

Paul Choi

Tazeen Ahmad

Judah Frommer

Samantha Corwin

Brian Cheng

Danielle Brill Bongero

David Lebowitz

Dingding Shi

Ellie Merle

Geoff Meacham

Geoffrey Meacham

Huidong Wang

Joon Lee

Joseph Thome

Khalil Fenina

Michael Riad

Richard Miller

Sami Corwin

Tiago Fauth

- PTC Therapeutics has secured US and European approvals for **Cefiance**, positioning it as a foundational product for future growth, and reported over **$1.9 billion** in cash on its balance sheet at the close of Q2.  **[1070081_tx_378141_0]** 
- Cefiance is projected to be at least a **$1 billion** commercial opportunity in the US, with an additional 50% of that ex-US, and initial launch metrics will be provided on the Q3 earnings call.  **[1070081_tx_378141_3]** 
- The company recently acquired Sensa to eliminate a high royalty on Cefiance, a transaction with a **20%+ IRR** based on consensus numbers for the **EUR 225 million** upfront payment.  **[1070081_tx_378141_8]** 
- Clinical data for Cefiance demonstrates significant efficacy, with **67%** of patients achieving a greater than 30% reduction in phenylalanine in the AFFINITY study, indicating its potential to address unmet needs across the full spectrum of PKU patients.  **[1070081_tx_378141_5]**

PTC Therapeutics Discusses Cefiance Launch and Financial Position

PTC THERAPEUTICS (PTCT)